Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

(Family Features) Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...